



## Metrion Biosciences appoints Mark Keogh as Non-Executive Director

*Appointment strengthens the financial and corporate experience of Metrion's Board in support of the Company's planned international growth*

**Cambridge, UK, 19 April 2021:** Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, today announced the appointment of Mark Keogh as a Non-Executive Director. The appointment follows the Company's recently announced £2.7m new equity investment led by Gresham House Ventures and is intended to strengthen the Board's financial and corporate experience, in support of the Company's planned international growth.


Mark is a chartered accountant and civil engineer with more than 30 years' experience of senior finance management in multiple industrial sectors. Most recently he was Group Chief Financial Officer of Charles Taylor plc, where he facilitated the group's rapid growth through multiple acquisitions and played a significant part in its eventual buy out by private equity funds. Prior to this he held roles including Group Managing Director and Finance Director of Warner Estate plc, Finance Director of Severn Trent Water, Finance Director of Mowlem Construction and CFO of BP Marine. Mark graduated in engineering from University College Dublin, is a member of the Institution of Engineers of Ireland and holds both ACA and chartered tax adviser qualifications.

**Dr Keith McCullagh, Chairman of Metrion Biosciences, said:** *"I am delighted to welcome Mark to the board of directors. Mark provided helpful advice to the Company as we concluded our recent investment round, and his appointment will enable us to continue to benefit from his substantial experience of business planning, financial operations, corporate finance and M&A. He will be an asset to the team and will contribute significantly to Metrion's further growth and international development."*

**Mark Keogh commented:** *"I'm thrilled to be joining Metrion at such an exciting time for the organisation. I look forward to working more closely with Keith and the Board, as well as the Company's excellent executive management team, to support the business as it executes its strategic growth objectives."*

**-ENDS-**

### Notes to Editors



For high resolution images please contact Zyme Communications

**Media contact:**

Katie Odgaard

Zyme Communications

E-mail: [katie.odgaard@zymecommunications.com](mailto:katie.odgaard@zymecommunications.com)

Tel: +44 (0)7787 502 947

*To opt-out from receiving press releases from Zyme Communications please email [info@zymecommunications.com](mailto:info@zymecommunications.com). To view our privacy policy, please [click here](#).*

**About Metrion Biosciences**

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit [www.metrionbiosciences.com](http://www.metrionbiosciences.com)

LinkedIn: [@metrion-biosciences](#) | Twitter: [@metrion\\_biosci](#)